Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gedivumab (MHAA4549A; RG7745), a human monoclonal antibody, exhibits high specificity in targeting the influenza A virus (IAV) by binding to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome, making Gedivumab useful for studies on IAV infection disease [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Gedivumab (MHAA4549A; RG7745), a human monoclonal antibody, exhibits high specificity in targeting the influenza A virus (IAV) by binding to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome, making Gedivumab useful for studies on IAV infection disease [1]. |
Molecular Weight | N/A |
CAS No. | 1807954-17-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gedivumab 1807954-17-1 inhibitor inhibit